Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients With HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab With Chemotherapy Plus Trastuzumab Plus Bevacizumab

NCT00625898 is registered in ClinicalTrials.gov with NSABP Foundation Inc as lead sponsor.

NCT NCT00625898
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00625898 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients With HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab With Chemotherapy Plus Trastuzumab Plus Bevacizumab
Lead sponsor
NSABP Foundation Inc
Phase
Phase 3
Overall status
Terminated
Start date
April 30, 2008
Completion date
July 31, 2014
Enrollment
3,509 (actual)
Sites
649

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer